Is Dupuytren’s an autoimmune or an allergic condition? In some fibrotic diseases, such as endomyocardial fibrosis, tissues show activity of eosinphils. Eosinophils are normally found in small numbers in the bloodstream. They are part of the immune system and are abnormally involved in some medical conditions such as asthma. Eosinophils
Dupuytren’s and Peyronie’s disease are believed to be related, to share a common genetic starting point. This has been an assumption, not hard fact: the genetic starting points of these conditions are not yet known, much less known to be the same. Doctors have been wrong on these issues in
Auxilium has moved closer to product availability of Xiaflex collagenase injection for the treatment of Dupuytren’s contracture by announcing the wholesale drug price: $3250.00 for a single treatment dose. For those who think that this seems high, consider this in perspective. There are many categories of pharmaceutical products. Most commonly
While researchers look through the microscope at the cellular biology of Dupuytren’s, surgeons look for clues using the fish eye lens of demographic observations. Who is at risk? What family, lifestyle, medication and medical condition issues affect the incidence and magnitude of Dupuytren’s? There is a long history of these
Sorting out the genetic basis of Dupuytren’s is not simply a matter of finding out which genes are involved. The goal is to understand the biochemistry of exactly what these specific genes do to either start or fail to stop the process of Dupuytren’s. Cell biology is always a domino
What is Dupuytren’s Diathesis? Diathesis is a medical term meaning tendency toward a condition. One way of describing a person with Dupuytren’s diathesis is that they have more of whatever Dupuytren’s is. Diathesis usually means more aggressive Dupuytren’s: earlier age of onset; more fingers involved; more often bilateral; faster progression;
Xiaflex (Collagenase) has finally been approved by the FDA for the treatment of Dupuytren’s contracture. When work began on the development of collagenase to treat Dupuytren’s contracture, the bar was pretty low: anything better than fasciectomy in terms of either safety or efficacy would be a great advance. No other
Two things are needed for people dealing with Dupuytren’s: a way to reverse or restore fingers back to their natural state and a way to prevent progression/recurrence. For the former, progress is being made; the latter remains the elusive goal of a cure. Dupuytren’s is a shrinking process. The ideal
Dupuytren’s is truly a biomechanical process, and the ultimate process has to do with the way that fibroblasts and myofibroblasts attach to each other and physically attach to strands of collagen and other components of the tissue matrix which surrounds them. An investigation into the complex junction of living cells,
- The association between echogenicity and progression of Dupuytren's disease (DD): Birth of an imaging biomarker?
- Is a smartphone application as accurate as a traditional goniometer for assessing finger joint angles in Dupuytren's disease?
- Dupuytren contracture after acute traumatic hand injury in an adolescent: A case report
- Patient Experiences With Hand Surgery in the Office Versus Ambulatory Surgery Center
- Collagenase Treatment Versus Needle Fasciotomy for Single-Digit Dupuytren Contractures: A Meta-Analysis of Randomized Controlled Trials